Dormancy signatures and metastasis in estrogen receptor positive and negative breast cancer - Wikidata - awgldk - TriplyDB

Dormancy signatures and metastasis in estrogen receptor positive and negative breast cancer

Dormancy signatures and metastasis in estrogen receptor positive and negative breast cancer

http://www.wikidata.org/entity/Q34243896

about

Tumor dormancy: potential therapeutic target in tumor recurrence and metastasis prevention Lipid-sensors, enigmatic-orphan and orphan nuclear receptors as therapeutic targets in breast-cancer Targeting dormant micrometastases: rationale, evidence to date and clinical implications Cancer Dormancy: A Regulatory Role for Endogenous Immunity in Establishing and Maintaining the Tumor Dormant State Mechanisms of disseminated cancer cell dormancy: an awakening field The gene desert mammary carcinoma susceptibility locus Mcs1a regulates Nr2f1 modifying mammary epithelial cell differentiation and proliferation NR2F1 controls tumour cell dormancy via SOX9- and RARβ-driven quiescence programmes.Human cancer growth and therapy in immunodeficient mouse models.Epsin Family Member 3 and Ribosome-Related Genes Are Associated with Late Metastasis in Estrogen Receptor-Positive Breast Cancer and Long-Term Survival in Non-Small Cell Lung Cancer Using a Genome-Wide Identification and Validation Strategy Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation Association of estrogen receptor-α A908G (K303R) mutation with breast cancer risk.Progesterone-inducible cytokeratin 5-positive cells in luminal breast cancer exhibit progenitor properties.Estrogen Receptor Status Predicts Late-Onset Skeletal Recurrence in Breast Cancer Patients Metastasis prevention by targeting the dormant niche.Tumour dormancy and clinical implications in breast cancer.Tumor cell dissemination: emerging biological insights from animal models and cancer patients.Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V.Breast cancer metastasis: issues for the personalization of its prevention and treatment.Activation of anaphase-promoting complex by p53 induces a state of dormancy in cancer cells against chemotherapeutic stress.Metastasis dormancy in estrogen receptor-positive breast cancer.Induction of LIFR confers a dormancy phenotype in breast cancer cells disseminated to the bone marrow.TGF-β2 dictates disseminated tumour cell fate in target organs through TGF-β-RIII and p38α/β signalling.The dormancy dilemma: quiescence versus balanced proliferation.Tumor metastasis: moving new biological insights into the clinic.Mechanisms of Metastatic Tumor Dormancy.Microenvironment in metastasis: roadblocks and supportive niches.Phenotypic heterogeneity of disseminated tumour cells is preset by primary tumour hypoxic microenvironments.Dormancy programs as emerging antimetastasis therapeutic alternatives.Metastasis awakening: targeting dormant cancer.New insights into tumor dormancy: Targeting DNA repair pathways.Predicting and Overcoming Chemotherapeutic Resistance in Breast Cancer.Replication-dependent histone isoforms: a new source of complexity in chromatin structure and function Enrichment and detection of bone disseminated tumor cells in models of low tumor burden STAT3 in Breast Cancer Onset and Progression: A Matter of Time and Context Key regulators of lipid metabolism drive endocrine resistance in invasive lobular breast cancer A facile in vitro platform to study cancer cell dormancy under hypoxic microenvironments using CoCl Metastasis: The rude awakening Cellular Phenotype Plasticity in Cancer Dormancy and Metastasis

P2860

Q21195742-18A3D948-D9DD-4C56-82CE-AB6214489106 Q26764743-761D3CB1-E490-4CFB-8F6A-24622F36B738 Q26765205-D42B1D24-2D1F-48AE-823E-281BF5CD583D Q26782573-D48745A5-30D7-4531-A51B-9CBBC82B2F66 Q27027015-C8B28037-F73B-45AC-A540-74F03D658E55 Q27322396-B11AC99D-E4A5-4613-BC86-45358CE675CC Q35037151-D71D1599-CA31-4E5E-A366-5010CAE3220B Q35545282-FE82BB48-B5A9-4DAB-8F7E-237A908A5B1F Q36215006-95C478BF-87D6-40D6-8985-64DA29DCB53B Q36288896-6959132C-179F-4C0C-951B-DE6BC56AA675 Q36298575-2918FD21-FFF9-44DF-98B5-B4DA980753EC Q36449789-6005D03D-72A8-48E0-87CF-5868219CBAA7 Q36547484-E08D71F3-CB10-449B-B4FD-700EAF10F1ED Q36653686-08134A29-F867-45D2-BCBC-23F3C9DD853F Q36829245-828BBB51-C1D9-4687-9D06-FF93B31E00A7 Q36863179-2918D214-57AB-4B24-9E67-F79D41F93FA6 Q36887350-94E63A0A-5AE1-43B5-BC18-52188C6278E9 Q37065597-6BA52F6D-7DCC-4D26-995F-B61A285324DD Q37218214-88EE4A36-42C5-449F-AC98-69A51361137B Q37295389-B51AE45C-BE5D-46E1-87BE-999A4362402E Q37427008-4E1A6C40-7984-4798-9017-B362F7F848E6 Q37710308-A104927D-7542-434B-B94F-0F4FD7A21846 Q37735525-5C0C3E82-9924-47B0-90A2-41EDDE953BB6 Q38116507-03406F75-1A82-4AD6-AB1B-5F88008CC881 Q38160740-447D6E5C-B423-4FCA-80F8-88476D3E166F Q38559618-B3FC3101-AC5F-401F-ABEF-8944504A4AFC Q38588066-186B3150-9AAE-4C20-9A06-1C2585DB4365 Q38719932-F51AD6D8-E4B1-4D48-8CE0-8B3478D3CF4C Q40630240-5E2C4C8D-88A6-4AE9-BB1D-9831B251BB70 Q43165982-0060200D-8524-4FE9-9020-7F9A17BE543C Q43227475-8E1C5BA8-DAA9-499D-8E1D-0CCF6C7E1D83 Q49544395-B97A3D3F-D543-4D20-A977-5C5C66CE4023 Q58700196-EB0BBDEA-FF4F-4238-BDDB-F95CF62C24BC Q58700560-EDAA2EA3-CB7C-4BF1-A5A3-723862EA7A05 Q58723081-393CBE85-D953-4C92-A4C9-66854F40E124 Q58765163-8A3561D3-DF47-4E53-A12C-E8CD219F844C Q58801300-7F0947B9-FB23-40E0-BA8E-8CB9490F243D Q59087301-662EB95D-B872-404B-B73A-EA417CB17BFE Q59136984-FAB859E7-E090-4FAC-A634-A17A2397224C

P2860

Dormancy signatures and metastasis in estrogen receptor positive and negative breast cancer

http://www.wikidata.org/entity/Q34243896

description

2012 nî lūn-bûn

@nan

2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Dormancy signatures and metast ...... ive and negative breast cancer

@ast

Dormancy signatures and metast ...... ive and negative breast cancer

@en

Dormancy signatures and metast ...... ive and negative breast cancer

@nl

type

label

Dormancy signatures and metast ...... ive and negative breast cancer

@ast

Dormancy signatures and metast ...... ive and negative breast cancer

@en

Dormancy signatures and metast ...... ive and negative breast cancer

@nl

prefLabel

Dormancy signatures and metast ...... ive and negative breast cancer

@ast

Dormancy signatures and metast ...... ive and negative breast cancer

@en

Dormancy signatures and metast ...... ive and negative breast cancer

@nl

P1433

Q34243896-AB10DAEF-1843-4273-A0B0-3AA671D1EF47

P1476

Q34243896-61CB2D80-26C9-45D7-BD8D-BE784B375525

P2093

Q34243896-456FF6C0-1CB1-4293-A226-E487A70D21F1

Q34243896-A1A6CD9B-3D0E-4228-8E3A-4681BBE42F5C

Q34243896-B16D9360-EB2D-4B14-BB0B-4C1449B4BB6B

Q34243896-E220F82B-87CE-4F24-8A91-5C38D8CAD9EA

Q34243896-F2C78589-7773-407F-A574-76657F8C7F76

P2860

Q34243896-1396D488-FE9C-439C-BFB4-3A5F4D4DB76A

Q34243896-18567797-A047-4601-A43A-82E627402FF0

Q34243896-26211B2C-1238-4F27-BB60-61653CB0DF63

Q34243896-27EFBB52-1D11-4587-92D7-7952CBBB5232

Q34243896-29C9A7A8-D16F-4560-9BAD-B053397230FB

Q34243896-4F8BE33F-0C6F-4FF5-845F-2ECC1B34E584

Q34243896-5331D456-B4E7-4549-AEB6-03EE90636979

Q34243896-5D0DF42A-496A-4288-BA4B-FD878FCAF118

Q34243896-5DEE6240-A172-453A-80D9-D1FC88F7ABB9

Q34243896-92CDCAFC-5D84-4DD9-B558-9CCD8561082A

P304

Q34243896-18CA2A9D-DD39-4584-8211-1E01ACED6C96

P31

Q34243896-7651F5D4-01D1-4EFE-ADD6-6DB0CBD068F0

P356

Q34243896-4633254C-719B-4DE5-B9C1-CBDEEEB4BC58

P407

Q34243896-514F295C-A989-40BD-B43C-44C0594C544E

P433

Q34243896-568C17E8-2D05-4041-BE45-B9C9C9137008

P478

Q34243896-940B1D36-EDC7-417C-B6BD-D5B88239DD85

P50

Q34243896-4919CE87-1858-406F-8358-27E82425D1D4

Q34243896-842A9F5D-E8F4-4FC2-9439-258F70EE2F4A

P577

Q34243896-A532536D-62B9-4784-B301-DE7864E98F4D

P5875

Q34243896-BCDFB98F-75F0-41E5-83AC-33AEF77984FC

P698

Q34243896-AE18182E-D8D8-46F3-8992-C7C741147409

P932

Q34243896-F2952A44-5874-4A1C-951C-7B7C2A61DCCC

P356

JOURNAL.PONE.0035569

P1433

P1476

Dormancy signatures and metast ...... ive and negative breast cancer

@en

P2093

Alvaro Avivar-Valderas

http://www.w3.org/2001/XMLSchema#string

Jeffrey E Segall

http://www.w3.org/2001/XMLSchema#string

Maria Soledad Sosa

http://www.w3.org/2001/XMLSchema#string

Ryung S Kim

http://www.w3.org/2001/XMLSchema#string

Yeriel Estrada

http://www.w3.org/2001/XMLSchema#string

P2860

A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis

A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes

Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts.

A gene-expression signature as a predictor of survival in breast cancer

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer

Mesenchymal stem cells promote mammosphere formation and decrease E-cadherin in normal and malignant breast cells.

Dissecting the metastatic cascade.

Luminal-B breast cancer and novel therapeutic targets.

The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression.

P304

e35569

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0035569

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Julio Aguirre-Ghiso

P577

2012-04-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

224822194

http://www.w3.org/2001/XMLSchema#string

P698

22530051

http://www.w3.org/2001/XMLSchema#string

P932

3329481

http://www.w3.org/2001/XMLSchema#string